GTC
SRNE

Ghost Tree Capital’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Ghost Tree Capital’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-30,000
Closed -$385K – 77
2014
Q1 		$385K Buy
+30,000
New +$332K 0.23% 62

Other funds holding SRNE

AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
TC
Talkot Capital Sausalito, California $73.7M AUM 8.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
B
Baird Milwaukee, Wisconsin $9.78B AUM 11.39% 1-Year Est. Return
HVC
Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return

Ghost Tree Capital's SRNE Position: Q2 2014 in Review

Ghost Tree Capital sold out of Sorrento Therapeutics, Inc. (SRNE) in Q2 2014, closing a stake of 30,000 shares — an estimated $385K sold.

Ghost Tree Capital first reported a position in SRNE in Q1 2014 and held it in 1 quarter. The position peaked at $385K in Q1 2014. 37 funds tracked by Wall St. Rank hold SRNE as of Q2 2014.

  • Ghost Tree Capital reported no remaining Sorrento Therapeutics, Inc. position as of Q2 2014 after selling out during the quarter.
  • Ghost Tree Capital sold 30,000 Sorrento Therapeutics, Inc. shares in Q2 2014, an estimated $385K.
  • Ghost Tree Capital first reported a position in Sorrento Therapeutics, Inc. in Q1 2014 and held it in 1 quarter.
  • Ghost Tree Capital's Sorrento Therapeutics, Inc. position peaked at $385K in Q1 2014.
  • 37 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q2 2014.

Based on Ghost Tree Capital's 13F filing for Q2 2014, filed 14 Aug 2014.